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Catatonia is a well-established psycho-motor disorder occurring in the background of various psychiatric and medical 
disorders. Catatonia is commonly associated with psychiatric disorders, especially affective disorders followed by 
schizophrenia. However, almost 20% occur in the background of different medical and neurological disorders which need to 
be properly examined and investigated. Catatonia is a serious medical and psychiatric emergency condition; most probably 
caused by alteration in GABAergic circuits and basal ganglia. If untreated, catatonia can cause life threatening complications 
like dyselectrolemia, respiratory aspiration, venous thromboembolism, acute renal failure and cardiac arrest because of poor 
oral intake, immobility and muscular rigidity. The risk of mortality or serious life threatening events further increases in cases 
of children and adolescents. In children and adolescents, thus, it becomes even more important to diagnose catatonia early 
and start appropriate treatment. Lorazepam is considered to be the first line treatment and is safe both in adults and children. 
But evidence is scarce for treatment of lorazepam-resistant adolescent Catatonia. In this report we discuss two adolescent 
patients diagnosed with catatonia with no medical or neurological disorders in the background. Neither of the patients 
responded to lorazepam alone or even after augmentation with second generation antipsychotic (olanzapine). Zolpidem, like 
lorazepam, has a positive allosteric effect on GABA A Receptors (GABAAR) and has been used in some cases successfully 
to treat resistant catatonia. Here we used zolpidem 30 mg/day in divided doses with marked improvement in few days in all 
the symptoms. Both cases were discharged on zolpidem extended release (ER) three times a day and maintained well through 
the next two follow ups in over a two month period. Zolpidem can be a good alternative for children and adolescents in 
resistant cases. 
 





Catatonia is a psychomotor disorder associated with 
various mental and neurological disorders. It is 
characterized by a variety of motor symptoms 
including stupor, posturing, catalepsy, waxy 
flexibility, mutism, negativism, mannerisms, 
stereotypic behaviour, and extreme agitation (1).  
Catatonia is a psychiatric emergency and it 
increases the risk of certain medical complications 
and mortality due to dehydration, immobility, and 
sympathetic nervous system hyperactivity, which are 
usually associated with catatonia. These conditions 
can lead to hypernatremia, pneumonia, 
rhabdomyolysis, sepsis, pulmonary embolism, renal 
and liver dysfunction, deep venous thrombosis, 
arrhythmia and neuroleptic malignant syndrome (2). 
It is found to be more severe in the younger age 
group (3). In adolescents it increases the risk of 
premature death up to 60 fold in comparison to the 
general population of the same sex and age (4). 
It becomes crucial to diagnose and treat adolescent 
catatonia early to avoid serious complications. 
Although DSM-5 (1) has no separate criteria for child 
and adolescent catatonia, it is challenging to identify 
adolescent catatonia in the early stages because its 
presentation might be different from adult catatonia, 
and it can be complicated by an existing 
developmental disorder. The commonly used scale 
for adults, Bush Francis Catatonia Rating scale 
(BFCRS), has also been used widely in children and 
adolescents (5). Cohen incorporated some changes in 
BFCRS to make it more child and adolescent 
oriented, including separating refusal to drink/eat 
from social withdrawal, replacing automatic 
obedience with automatic compulsive behaviour, 
adding incontinence as a regressive behaviour of 





catatonia. The resulting instrument is a modified 
version of the BFCRS called the Paediatric Catatonia 
Rating Scale (6).  
Benzodiazepines are the mainstay treatment for 
catatonia in adults (7) as well as in children (8). 
Augmenting lorazepam with second generation 
antipsychotics can be helpful. Although 
antipsychotics increase the risk of side effects 
including malignant catatonia and neuroleptic 
syndrome (6), favourable results have been found in 
some lorazepam-resistant cases (9). Zolpidem is 
another alternative in resistant cases. Zolpidem 
challenge test is found to be useful in initial 
improvement in symptoms and hence in diagnosing 
catatonia in adults (10) as well as in adolescents (11). 
There are case reports which showed a beneficial 
effect of zolpidem in treatment of catatonia (12). 
Here we present two adolescent cases of acute onset 
catatonia with no underlying neurological cause, who 
were initially tried on lorazepam with no or minimal 
improvement. With close monitoring of side effects 
by regular examination and relevant investigations in 
both patients, lorazepam was augmented with 
second generation antipsychotic. They showed no 
improvement with the combination, and then 
zolpidem was started after favourable results of a 
zolpidem challenge test.  
 
Case 1  
Background  
A 15-year-old adolescent female from an urban 
background presented with an acute onset illness of 
around one month duration. There was no history 
suggestive of any past psychiatric, medical or 
neurological disorder, any substance use, childhood 
trauma or any other contributory personal or family 
history. The illness started acutely with irritability, 
unprovoked physical aggression, undressing herself 
in public and inability to sleep. Toward the end of the 
last week before presentation to the emergency 
department, she developed decreased social 
interaction, inability to speak, maintaining a posture 
for long time, decreased oral intake, and sudden 
unprovoked undirected agitated behaviour. 
 
Presentation and assessment  
The patient presented in the emergency department 
of a tertiary neuropsychiatry centre. On examination, 
she showed mutism, active negativism, withdrawn 
behaviour, staring, posturing, and rigidity of all the 
limbs; BFCRS Score was 20. No other neurological 
sign was found. Vitals including blood pressure, 
pulse rate, temperature and SpO2 were within 
normal limits.  
Initial investigations including Complete Blood 
Counts (CBC), Random Blood Sugar (RBS), Liver 
Function Test (LFT), Kidney Function Test (KFT), 
Serum Electrolytes (SE), Serum Ammonia, Creatine 
Phosphokinase (CPK) and Non Contrast Computed 




On the basis of examination and investigations a 
provisional diagnosis of catatonia was entertained in 
the background of psychosis and the patient was 
shifted to a psychiatric unit for further evaluation and 
management. After favourable results with a 
lorazepam challenge test, she was started on 
lorazepam 2 mg intravenously three times a day along 
with supportive therapy. The patient was observed 
for next 2 days on the same regimen on which she 
would show only transient improvement (lasting for 
20-40 minutes) in mutism and oral intake after 
lorazepam injection with no response in other 
catatonic symptoms. Intravenous lorazepam was 
augmented with an oral second generation 
antipsychotic (SGA). Olanzapine 10 mg/day resulted 
in no added response in any of the symptoms for the 
next 3 days. The patient was planned to start on 
zolpidem therapy before use of Electroconvulsive 
Therapy (ECT), as use of ECT is restricted in 
children and adolescents as per Mental Healthcare 
Act 2017 of the government of India. 
She was given a zolpidem challenge test on the 6th 
day with a 10 mg Immediate Release (IR) tablet, after 
which she showed some improvement in rigidity, 
posturing and mutism in the next 30 minutes. She 
was then started on oral zolpidem IR 30 mg/day in 
divided doses along with oral olanzapine 10 mg/day. 
Intravenous lorazepam was gradually stopped. After 
3 days of zolpidem, she had shown complete 
response in all the catatonic symptoms. She was 
discharged on oral zolpidem Extended Release (ER) 
12.5 mg three times a day along with olanzapine 10 
mg/day. The patient maintained well for the next 
two months during follow-ups and thereafter 




The second case was a 14-year-old adolescent male. 
Similar to the previous case, there was no history 
suggestive of any past psychiatric, medical or 
neurological disorder, any substance use, childhood 
trauma or any other contributory personal or family 
history. He had history of acute onset illness of 20 
days duration, which started with remaining 
withdrawn, decreased verbal output and decreased 
oral intake. Symptoms worsened after a week, and 
gradually he completely stopped taking food or drink 
orally, stopped interacting with anyone both verbally 
and non-verbally, would maintain a posture for long 
time and later on started repeating the same phrases 





or words again and again without any stimuli and 
developed stiffness in whole body. 
 
Presentation and assessment 
The patient presented in the emergency department 
of a tertiary neuropsychiatry centre on around the 
20th day of illness. On examination all the vitals 
including blood pressure, pulse rate, temperature, 
and SpO2 were within normal limits. On mental 
status examination, mutism, negativism, withdrawn 
behaviour, posturing, occasional episodes of verbal 
stereotypy, and rigidity of all the limbs were found, 
BFCRS Score was 22. No other neurological sign was 
established. Initial investigations including CBC, 
RBS, LFT, KFT, S.E., S. Ammonia, CPK and NCCT 
head were within normal limits. 
 
Management   
The patient was provisionally diagnosed as a case of 
catatonia and shifted to the Psychiatric Unit. A 
lorazepam challenge test was given, and he showed 
some improvement in oral intake 15 minutes after 
the injection. He was started on intravenous 
lorazepam 2 mg three times a day along with 
supportive therapy. By the next week he showed 
improvement in oral intake and started taking food 
by himself (BFCRS=18), but there was no 
improvement in any other catatonic symptoms. Thus 
intravenous lorazepam was augmented with 
olanzapine 10 mg/day. In the 2nd week he showed 
improvement in verbal stereotypy apart from oral 
intake, but all other symptoms persisted. Moreover 
he developed abnormal behaviour of persistent 
pacing around the ward which was considered a part 
of olanzapine induced akathisia, and olanzapine was 
stopped. The patient was kept on intravenous 
lorazepam 6 mg/day and propranolol up to 40 mg 
with no improvement in the next 4 days. All the 
investigations were repeated along with serum 
ceruloplasmin, serum copper, 24 hour urinary 
copper, and MRI of the brain to rule out other causes 
of movement disorder. All the investigations were 
within normal limits and the brain MRI showed no 
significant changes. After ruling out all the causes, 
persistent pacing behaviour was considered to be an 
automatic compulsive movement which can be seen 
in children and adolescents with catatonia. The 
patient was resistant to intravenous lorazepam alone 
and with olanzapine. In this case also, zolpidem 
challenge test was performed, and some 
improvement was observed in pacing behaviour and 
mutism after about 30 minutes. Henceforth he was 
started on oral zolpidem IR 30 mg/day in divided 
doses, and over the next week, the patient showed 
significant improvement in all the catatonic 
symptoms with no significant side effects. The 
patient was discharged on oral zolpidem ER 12.5 mg 
three times a day and remained asymptomatic for 
next 2 months of follow-ups, after which zolpidem 
was tapered off and stopped. 
 
Discussion: 
Catatonia effectively responds to lorazepam and 
ECT, and lorazepam is considered as first line 
treatment irrespective of the underlying cause (7). 
Although benzodiazepines are used extensively to 
treat catatonia and accepted to be a first choice, they 
demonstrate around only 79% remission rate (13). 
The exact pathophysiology of catatonia is unclear, 
but there are some proposed theories of underlying 
mechanism. It has been proposed that catatonia is 
the result of motor manifestations of intense inner 
anxiety(14). Hence, benzodiazepines through 
facilitatory action on the GABA-A Receptor 
(GABAAR) improve the catatonic symptoms (15).  
It is also proposed that the catatonia is 
characterized by hypokinetic and hyperkinetic 
movements similar to Parkinson’s disease which is 
suggestive of dysfunction of different neuronal 
motor circuits. One of the important circuits which 
can be included in causing inhibition and excitation 
of movements, comprises a circuit from the primary 
motor cortex (PMC) to the thalamus, and back to the 
PMC. Another circuit, corticocortical circuit, is 
considered to control motor organisation and speed, 
and includes the PMC, the supplementary motor area 
(SMA), and the medial prefrontal cortex (16). The 
SMA is found to initiate the inhibitory process to the 
basal ganglia, and automatic motor control depends 
on the concentration of GABAAR in the SMA (17). 
Reduced concentration of GABAAR is found in the 
SMA and motor cortical areas in cases of catatonia 
(18). The decreased concentration of GABAAR in 
the SMA and motor cortex leads to decreased 
inhibition, initiation, and control of motor 
movements, and this possibly leads to symptoms of 
catatonia. Benzodiazepines increase inhibitory action 
in the CNS through their positive allosteric action on 
GABAAR, a pentameric ligand gated channel. A total 
of 19 subunits of GABAAR have been identified (α1-
α6, β1- β3, γ1-γ3, δ, ε, π, θ, ρ1-ρ3) which in different 
combinations form a multitude of GABAAR 
subtypes. Benzodiazepines non-specifically bind to 
the α(+)/γ2(−) subunit interface in different 
subtypes of GABAAR (19).  
Here we had two adolescent cases who did not 
respond to the first line treatment of lorazepam alone 
for adequate dose and duration nor along with a SGA 
as an augmenting agent. Both patients showed 
significant improvement with zolpidem therapy (30 
mg/day) in the next 3-4 days with no significant side 
effects and also remained asymptomatic on zolpidem 
ER 12.5 mg three times a day for the next two 





months of follow up without any significant side 
effects.  
Zolpidem like benzodiazepines is a positive 
allosteric modulator of GABA-A receptors, but it 
specifically binds to the alpha 1 subunit of GABAAR 
unlike lorazepam which non-specifically binds to 
different subtypes of GABAAR (20). Zolpidem has 
already  been used successfully in cases where 
benzodiazepines  were not effective (10, 12). The 
zolpidem challenge test is also proposed for catatonia 
screening based on existing studies. For example, a 
French study confirmed prompt response within 20 
minutes after zolpidem administration in all patients 
(21), and a beneficial response was seen in other case 
reports(11, 12).  
By reviewing the neuropathology of catatonia, 
action of benzodiazepines and zolpidem, and seeing 
improvement with zolpidem in many cases along 
with the response seen in our two lorazepam-
resistant cases, we can arrive at following 
possibilities: 
(I)  In different patients, catatonia might occur 
through deficiency of different subtypes of 
GABAAR 
(II) In some cases, catatonia might occur through 
specific deficiency of the alpha 1 subunit of 
GABAAR 
(III) Zolpidem may be beneficial in lorazepam-
resistant cases of catatonia in children and 
adolescents. It can be tried before ECT and in 
cases where ECT is contraindicated or 
restricted 
 
Although the evidence in the favour of zolpidem 
for treatment of catatonia is scarce, it may be an 
effective treatment in lorazepam-resistant cases, 
especially in children and adolescents. Larger studies 
are required to confirm zolpidem’s efficacy. 
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